Itamar Medical Launches WatchPAT 300

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

Itamar Medical Ltd. today announced the launch of WatchPAT 300, the next generation WatchPAT system for home sleep apnea testing. WatchPAT 300 includes several advances that are designed to enhance both patients’ WatchPAT experience as well as provide physicians with a trusted and cost-effective method for rapid, scalable and effective diagnosis of sleep apnea. Itmar is a (Nasdaq & TASE: ITMR), company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market.

“Sleep apnea has reached epidemic levels and is estimated to affect 25 percent of adults worldwide,” said Gilad Glick, President and CEO of Itamar Medical. “This has significant health and economic implications, as half of all patients with cardiovascular disease are believed to suffer from sleep apnea and the total cost of unmanaged obstructive sleep apnea is $150 billion each year in the United States alone. Addressing the challenge of efficiently and cost-effectively diagnosing the millions of patients with undiagnosed sleep apnea requires a simple, accurate and scalable modality. We believe that WatchPAT 300 – which demonstrates Itamar Medical’s continued commitment to innovation focused on meeting the needs of patients, health systems, payers and physicians – can play a critical role in solving this challenge.”

WatchPAT 300 utilizes peripheral arterial tone and other signals to calculate True Sleep Time and Complete Sleep Architecture to accurately and reliably diagnose both obstructive and central sleep apnea.

WatchPAT 300 has an intuitive and more comfortable design with three points of contact and without cumbersome nasal canula or chest belts to ensure patient ease of use. It is based on the peripheral arterial tone signal (PAT) and uses its advanced actigraphy to differentiate between wake and sleep periods to calculate true sleep time. WatchPAT 300 also uses the PAT amplitude and pulse rate to differentiate between non-rapid eye movement (REM) and REM sleep. It also provides clinically validated sleep architecture, based on sleep stages, including sleep efficiency, sleep latency and REM latency. Its total sleep time reduces the risk of misdiagnosis and misclassification that has been reported to be 20 percent in studies using total recording time. WatchPAT 300 also includes a Central+ module, which enables specific identification for Central Sleep Apnea events. Its one-stop preparation comes with a significantly faster download and automated study preparation time to improve workflow.

WatchPAT 300 was granted 510(k) clearance by the U.S. Food and Drug Administration on August 17, 2018 and will gradually replace the current WatchPAT 200 platform and will be presented at SLEEP 2019 on June 8-12 in San Antonio, TX (booth # 916). WatchPAT 300 will be compatible with zzzPATTM software and CloudPATTM, Itamar Medical’s cloud-based IT solution for convenient sleep diagnosis and secure patient data transfers to streamline workflow.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles